Posttransplant reduction in preexisting donor‐specific antibody levels after belatacept‐ versus cyclosporine‐based immunosuppression: Post hoc analyses of BENEFIT and BENEFIT‐EXT

BENEFIT and BENEFIT‐EXT were phase III studies of cytotoxic T‐cell crossmatch–negative kidney transplant recipients randomized to belatacept more intense (MI)‐based, belatacept less intense (LI)‐based, or cyclosporine‐based immunosuppression. Following study completion, presence/absence of HLA‐speci...

Descripción completa

Detalles Bibliográficos
Autores principales: Bray, R. A., Gebel, H. M., Townsend, R., Roberts, M. E., Polinsky, M., Yang, L., Meier‐Kriesche, H.‐U., Larsen, C. P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Brief Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6055813/
https://www.ncbi.nlm.nih.gov/pubmed/29573335
http://dx.doi.org/10.1111/ajt.14738

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6055813/
https://www.ncbi.nlm.nih.gov/pubmed/29573335
http://dx.doi.org/10.1111/ajt.14738

Ejemplares similares